CN116425720A - Preparation method of delafloxacin meglumine - Google Patents

Preparation method of delafloxacin meglumine Download PDF

Info

Publication number
CN116425720A
CN116425720A CN202210004950.6A CN202210004950A CN116425720A CN 116425720 A CN116425720 A CN 116425720A CN 202210004950 A CN202210004950 A CN 202210004950A CN 116425720 A CN116425720 A CN 116425720A
Authority
CN
China
Prior art keywords
reaction
compound
acid
organic solvent
hydroxyazetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210004950.6A
Other languages
Chinese (zh)
Inventor
王仲清
黎利军
范文进
唐鹏飞
郑金付
漆春辉
肖毅
吴警
黎义绍
黄芳芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Priority to CN202210004950.6A priority Critical patent/CN116425720A/en
Publication of CN116425720A publication Critical patent/CN116425720A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a new preparation method of delafloxacin meglumine, which adopts cheap 2,4, 5-trifluoro benzoic acid as a starting material, and the target product delafloxacin meglumine is obtained through 7 steps of reactions, and the total yield is as high as 85% -95%. In addition, the purity of the delafloxacin meglumine obtained by the method is more than 99%. The preparation method adopts multi-step continuous casting, has simple operation, low cost of required equipment and raw materials, convenient post-treatment of each step and higher purity of the intermediate.

Description

Preparation method of delafloxacin meglumine
Technical Field
The invention relates to the technical field of medicines, in particular to a preparation method of delafloxacin meglumine.
Background
Delafloxacin (delafloxacin) was developed by Wakunaga pharmaceutical company, and a new generation of broad-spectrum fluoroquinolone antibiotics developed by later-authorized melita pharmaceutical company. In 2017, delafloxacin (trade name Baxdela TM ) Are marketed for the treatment of acute bacterial skin and skin structure infections caused by susceptible bacteria. Compared with other fluoroquinolone antibacterial drugs, delafloxacin has more excellent activity against gram-positive bacteria.
The chemical formula of delafloxacin is: 1- (6-amino-3, 5-difluoropyridin-2-yl) -6-fluoro-7- [3- (isobutyryloxy) azetidin-1-yl ] -4-oxo-1, 4-dihydroquinoline-3-carboxylic acid ethyl ester, having the structure:
Figure BDA0003455167710000011
WO9711068 discloses a process for the preparation of delafloxacin, the synthetic route of which is shown below:
Figure BDA0003455167710000012
the synthetic route is characterized in that the chlorine atom on the Yu Dela quinoline benzene ring is introduced by a substrate 3-chloro-2, 4, 5-trifluoro-benzoic acid. However, the cost of using 3-chloro-2, 4, 5-trifluorobenzoic acid as a reaction raw material is high. Furthermore, the patent does not disclose the meglumine salt of delafloxacin.
CN108084161a discloses a preparation method of delafloxacin meglumine, the synthetic route of which is shown as follows:
Figure BDA0003455167710000021
the synthetic route still uses 3-chloro-2, 4, 5-trifluoro-benzoic acid as a reaction raw material, and has high cost. Furthermore, the total yield of final product delafloxacin meglumine is only about 60%, which is low.
Therefore, there is a need to develop a new process for the preparation of delafloxacin meglumine at lower cost and with higher overall yields.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a novel preparation method of delafloxacin meglumine, which adopts cheap 2,4, 5-trifluoro-benzoic acid as a starting material, and obtains the target product delafloxacin meglumine through 7 steps of reactions, wherein the total yield is as high as 85% -95%.
In order to achieve the above object, the present invention provides the following technical solutions.
A process for the preparation of delafloxacin meglumine comprising:
step a: reacting reactant II with an acyl chloride reagent to form compound III;
step b: by reacting compound III with N, N-dimethylaminoacrylic acid C 1 -C 6 Alkyl ester reacts to generate a compound IV;
step c: reacting compound IV with 2, 6-diamino-3, 5-difluoropyridine to form compound V;
step d: the compound V is subjected to ring-closure reaction in the presence of alkali to obtain a compound VI;
step e: the acid addition salt of 3-hydroxy azetidine is subjected to substitution reaction with a compound VI, and the obtained substituted product is subjected to acylation reaction with an acylating agent, so that a compound VII is obtained;
step f: the compound VII and a chlorinating agent are subjected to chlorination reaction on a benzene ring, and the obtained product is subjected to hydrolysis reaction in the presence of alkali, so that the compound VIII is obtained; and
step g: reacting compound VIII with meglumine to form a salt to give delafloxacin meglumine of formula I:
Figure BDA0003455167710000031
wherein R may be C 1 -C 6 Alkyl or phenyl.
Preferably, the acid chloride reagent in step a may be thionyl chloride, oxalyl chloride, phosphorus trichloride or phosphorus pentachloride. In some embodiments, the acid chloride reagent in step a is thionyl chloride.
Preferably, the molar ratio of reactant II to the acid chloride reagent is 1 (1-2), preferably 1 (1.2-1.5). Specifically, the molar ratio of reactant II to the acid chloride reagent may be 1:2, 1:1.9, 1:1.8, 1:1.7, 1:1.6, 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, or 1:1.
Preferably, the reaction of step a is carried out in an organic solvent selected from one or more of Dichloromethane (DCM), toluene, acetonitrile and N, N-Dimethylformamide (DMF). Specifically, the organic solvent may be a mixture of dichloromethane and N, N-dimethylformamide, a mixture of toluene and N, N-dimethylformamide, or a mixture of acetonitrile and N, N-Dimethylformamide (DMF). The reaction temperature in step a may be from 0 to 200 ℃, preferably from 0 to 100 ℃, more preferably from 5 to 80 ℃. The reaction time in step a may be from 1 to 48 hours, preferably from 1 to 24 hours. In some embodiments, step a comprises: mixing the compound II with an organic solvent, stirring and cooling, dropwise adding an acyl chloride reagent dissolved in the organic solvent, and heating and refluxing for reaction after the dropwise adding is finished.
Preferably, after the reaction of step a is completed, distillation under reduced pressure is performed. The temperature of the reduced pressure distillation may be 30 to 100 ℃, preferably 30 to 80 ℃.
Preferably, N, N-dimethylaminoacrylic acid C 1 -C 6 The alkyl ester may be N, N-dimethylaminomethyl acrylate, N-dimethylaminoethyl acrylate, N-dimethylaminopropyl acrylate, N-dimethylaminobutyl acrylate, N-dimethylaminopentyl acrylate or N, N-dimethylaminohexyl acrylate. In some embodiments, N, N-dimethylaminoacrylic acid C 1 -C 6 The alkyl ester is N, N-dimethylamino ethyl acrylate.
Preferably, compound III is reacted with N, N-dimethylaminoacrylic acid C 1 -C 6 Molar ratio of alkyl esters1 (1-1.5), preferably 1 (1-1.3). Specifically, compound III and N, N-dimethylaminoacrylic acid C 1 -C 6 The molar ratio of alkyl esters may be 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, or 1:1. In some embodiments, the N, N-dimethylaminoacrylic acid C 1 -C 6 The alkyl ester is N, N-dimethylamino ethyl acrylate.
Preferably, the reaction of step b is carried out in an organic solvent selected from one or more of dichloromethane, toluene, acetonitrile, triethylamine (TEA), N-dimethylformamide and N, N-dimethylacetamide. Specifically, the organic solvent may be a mixture of any one or more of dichloromethane, toluene and acetonitrile with any one or more of Triethylamine (TEA), N-dimethylformamide and N, N-dimethylacetamide. For example, the organic solvent may be a mixture of dichloromethane and triethylamine, toluene and triethylamine, acetonitrile and triethylamine, or the like. The reaction temperature in step b may be from 0 to 200 ℃, preferably from 20 to 100 ℃, more preferably from 20 to 80 ℃. The reaction time in step b may be from 1 to 24 hours, preferably from 1 to 12 hours. In some embodiments, step b comprises: n, N-dimethylaminoacrylic acid C 1 -C 6 The alkyl ester is mixed with the organic solvent, the compound III dissolved in the organic solvent is dripped into the obtained mixture, and after the dripping is finished, the temperature is raised for reaction.
Preferably, after the reaction of step b is completed, distillation under reduced pressure is performed. The temperature of the reduced pressure distillation may be 30 to 100 ℃, preferably 30 to 80 ℃.
Preferably, the molar ratio of compound IV to 2, 6-diamino-3, 5-difluoropyridine is 1 (1-1.5), preferably 1 (1-1.2). Specifically, the molar ratio of compound IV to 2, 6-diamino-3, 5-difluoropyridine may be 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, or 1:1.
Preferably, the reaction of step c is carried out in an organic solvent selected from one or more of acetonitrile, N-methylpyrrolidone (NMP), glacial acetic acid, anhydrous formic acid, tetrahydrofuran, ethyl acetate and ethanol. Specifically, the organic solvent may be a mixture of one or two of glacial acetic acid and anhydrous formic acid and one or more of acetonitrile, N-methylpyrrolidone, tetrahydrofuran, ethyl acetate and ethanol. For example, the organic solvent may be a mixture of acetonitrile and glacial acetic acid, a mixture of N-methylpyrrolidone and glacial acetic acid, a mixture of tetrahydrofuran and glacial acetic acid, a mixture of ethyl acetate and glacial acetic acid, or a mixture of ethanol and glacial acetic acid. The reaction temperature in step c may be from 0 to 80℃and preferably from 15 to 60 ℃. The reaction time in step c may be from 5 to 24 hours. In some embodiments, step c comprises: mixing the compound IV with an organic solvent, dropwise adding 2, 6-diamino-3, 5-difluoropyridine dissolved in the organic solvent into the obtained mixture at the temperature of 0-20 ℃, and heating for reaction after the dropwise adding is finished.
Preferably, after the reaction of step c is completed, the resulting mixture is cooled, and water is added dropwise thereto, and after stirring and filtration, the resulting cake is mixed with ethanol, and after filtration, dried.
Preferably, the base in step d is selected from K 2 CO 3 、Na 2 CO 3 NaOH and NaHCO 3 One or more of the following.
Preferably, the reaction of step d is carried out in an organic solvent selected from one or more of N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, N-dimethylformamide and N, N-dimethylacetamide. The reaction temperature in step d may be from 0 to 100 ℃, preferably from 20 to 50 ℃; the reaction time may be 1 to 10 hours.
Preferably, after the reaction of step d is completed, the resulting mixture can be directly used for the next reaction without any post-treatment.
Preferably, the acid addition salt of 3-hydroxyazetidine may be 3-hydroxyazetidine hydrochloride, 3-hydroxyazetidine sulfate, 3-hydroxyazetidine nitrate, 3-hydroxyazetidine sulfonate, 3-hydroxyazetidine mesylate, or 3-hydroxyazetidine succinate. In some embodiments, the acid addition salt of 3-hydroxyazetidine is 3-hydroxyazetidine hydrochloride.
Preferably, the molar ratio of compound VI to the acid addition salt of 3-hydroxyazetidine is 1 (1-1.5), preferably 1 (1-1.2). Specifically, the molar ratio of compound VI to the acid addition salt of 3-hydroxyazetidine may be 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, or 1:1.
Preferably, the substitution reaction in step e is carried out in an organic solvent selected from one or more of N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, N-dimethylformamide and N, N-dimethylacetamide. The substitution reaction in step e may be carried out in the presence of a base selected from K 2 CO 3 、Na 2 CO 3 NaOH and NaHCO 3 One or more of the following. The temperature of the substitution reaction may be 20-100 ℃, preferably 50-100 ℃. The time for the substitution reaction may be 1 to 5 hours.
Preferably, after completion of the substitution reaction in step e and before the acylation reaction, the reaction mixture is filtered while hot to obtain a filtrate.
Preferably, the acylating reagent in step e may be acetic anhydride, propionic anhydride, isopropyl anhydride, butyric anhydride isobutyric anhydride, pivalic anhydride, hexanoic anhydride, benzoic anhydride, acetyl chloride or benzoyl chloride. In some embodiments, the acylating reagent is acetic anhydride. The molar ratio of substitution product to acylating agent may be 1 (1-3), preferably 1 (1-2.5). Specifically, the molar ratio of substitution product to acylating agent may be 1:3, 1:2.9, 1:2.8, 1:2.7, 1:2.6, 1:2.5, 1:2.4, 1:2.3, 1:2.2, 1:2.1, 1:2, 1:1.9, 1:1.8, 1:1.7, 1:1.6, 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, or 1:1. The temperature of the acylation reaction may be 20-50 ℃, preferably 20-30 ℃; the reaction time may be 0.5 to 3 hours.
Preferably, after the acylation reaction is completed, an acid (e.g., citric acid or hydrochloric acid) is added dropwise to the resultant mixture, and after filtration, the resultant cake is mixed with toluene and ethanol, filtered again, and dried.
Preferably, the chlorinating agent in step f may be N-chlorosuccinimide (NCS). Preferably, the molar ratio of compound VII to chlorinating agent is 1 (1-1.5), preferably 1 (1-1.2). Specifically, the molar ratio of compound VII to chlorinating agent may be 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1 or 1:1.
Preferably, the chlorination in step f is carried out in an organic solvent, which may be ethyl acetate, ethanol, acetonitrile, chloroform, tetrahydrofuran, carbon tetrachloride, dichloromethane, DMF or DME. In some embodiments, the organic solvent is ethyl acetate. The chlorination reaction is carried out under strong acid conditions, for example in the presence of concentrated sulfuric acid. The temperature of the chlorination reaction can be 0-20 ℃; the reaction time may be 2 to 6 hours.
Preferably, after the chlorination reaction is completed, quenching and liquid separation are performed, and the resulting organic phase is concentrated.
Preferably, the base in step f may be selected from K 2 CO 3 、Na 2 CO 3 NaOH and NaHCO 3 One or more of the following. In some embodiments, the base in step f is NaHCO 3 . The temperature of the hydrolysis reaction can be 30-60 ℃; the reaction time may be 2 to 6 hours.
Preferably, after the hydrolysis reaction is completed, the resulting reaction mixture is filtered, preferably while hot; and acid (e.g., citric acid or hydrochloric acid) is added dropwise to the obtained filtrate, and the filtrate is filtered again and dried. Preferably, the temperature is reduced prior to filtration.
Preferably, the molar ratio of compound VIII to meglumine is 1 (1-1.5), preferably 1 (1-1.2). Specifically, the molar ratio of compound VIII to meglumine may be 1:1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1 or 1:1.
Preferably, the reaction of step g is carried out in a solvent which may be selected from one or more of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran and water. Specifically, the solvent may be a mixture of water and any one or more of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran. For example, the solvent may be a mixture of methanol and water, ethanol and water, isopropanol and water, acetone and water, acetonitrile and water, or tetrahydrofuran and water. The reaction temperature in step g may be 30-70 ℃; the reaction time may be 1 to 5 hours. In some embodiments, compound VIII is mixed with a solvent, warmed, and meglumine dissolved in the solvent is added dropwise to the reaction mixture, and the reaction is incubated.
Preferably, after the reaction of step g is completed, cooling, filtering and drying are performed.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention provides a new preparation method of delafloxacin meglumine, which adopts cheap 2,4, 5-trifluoro benzoic acid as a starting material, and the target product delafloxacin meglumine is obtained through 7 steps of reactions, wherein the total yield is as high as 85% -95%. In addition, the purity of the delafloxacin meglumine obtained by the method is more than 99%.
2. The preparation method adopts multi-step continuous casting, has simple operation, low cost of required raw materials and equipment, convenient post-treatment of each step and higher purity of the intermediate.
Detailed Description
In order to make the contents of the present invention more easily understood, the technical scheme of the present invention will be further described with reference to the specific embodiments, but the present invention is not limited thereto. All techniques implemented based on the above description of the invention are intended to be included within the scope of the invention. Unless otherwise indicated, the raw materials and reagents used in the examples were all commercially available. The reagents, instruments or procedures not described herein are those routinely determinable by one of ordinary skill in the art.
Example 1: synthesis of Compound III
To a 100mL single vial was added compound II (5.00 g,28.39 mmol), DCM (15 mL) and DMF (0.15 mL), and a solution of thionyl chloride (5.07 g,42.59 mmol) in DCM (10 mL) was slowly added dropwise with stirring and cooling to 5 ℃. After the dripping is finished, the temperature is raised to 40 ℃ for reflux reaction for 10 hours, and the mixture is distilled under reduced pressure at 30-40 ℃ until no fraction flows out, so that light yellow oily matter is obtained and is directly used for the next step.
Example 2: synthesis of Compound III
To a 250mL single-necked flask, a solution of Compound II (20.00 g,113.58 mmol), toluene (100 mL) and DMF (0.6 mL) was added dropwise with stirring to reduce the temperature to 5℃and a solution of thionyl chloride (20.27 g,170.37 mmol) in toluene (40 mL) was slowly added dropwise. After the dripping is finished, the temperature is raised to 80 ℃ for reaction for 3 hours, and the mixture is distilled under reduced pressure at 40-80 ℃ until no fraction flows out, so that yellow oily matter is obtained and is directly used for the next step.
Example 3: synthesis of Compound IV
To a 100mL single-port flask was added N, N-dimethylaminoethyl acrylate (4.06 g,28.39 mmol), TEA (3.16 g,31.23 mmol) and DCM (15 mL), and a solution of the whole oil (28.39 mmol) prepared in example 1 in DCM (10 mL) was added dropwise at room temperature. After the dripping is finished, the temperature is raised to 50 ℃ for violent reflux reaction for 6 hours, and the mixture is distilled under reduced pressure at 30-40 ℃ until no fraction flows out, so that a reddish brown oily substance is obtained and is directly used for the next step.
Example 4: synthesis of Compound IV
To a 250mL single-necked flask were added N, N-dimethylaminoethyl acrylate (16.26 g,113.58 mmol), TEA (12.64 gg,124.94 mmol) and toluene (60 mL), and a toluene (40 mL) solution of the total oil (113.58 mmol) prepared in example 2 was added dropwise at room temperature; after the dripping is finished, the temperature is raised to 50 ℃ for reaction for 6 hours, and the mixture is distilled under reduced pressure at 40-60 ℃ until no fraction flows out, so that a reddish brown oily matter is obtained and is directly used for the next step.
Example 5: synthesis of Compound V
All of the oil (28.39 mmol) from example 3 was mixed with acetonitrile (25 mL) and glacial acetic acid (2.69 g,44.72 mmol) and a solution of 2, 6-diamino-3, 5-difluoropyridine (4.32 g,29.77 mmol) in acetonitrile (25 mL) was added dropwise at 15 ℃. After the completion of the dropwise addition, the temperature was raised to 55℃and the reaction was carried out for 16.0 hours. Cooling to 20 ℃, dropwise adding water (50 mL), stirring for 30min, filtering, pulping a filter cake with 95% ethanol (30 mL) at room temperature for 1h, suction filtering, and vacuum drying the filter cake at 60 ℃ for 12h to obtain 10.85g of bright yellow solid with purity of 99.23% and yield of 95.2% (namely, the total yield of three steps of examples 1, 3 and 5).
Example 6: synthesis of Compound V
All of the oil (113.58 mmol) from example 4 was mixed with NMP (100 mL) and glacial acetic acid (10.23 g,170.36 mmol) and a solution of 2, 6-diamino-3, 5-difluoropyridine (17.30 g,119.22 mmol) in NMP (100 mL) was added dropwise at 15 ℃. After the completion of the dropwise addition, the temperature was raised to 55℃and the reaction was carried out for 16.0 hours. Cooling to 20 ℃, dropwise adding water (200 mL), stirring for 30min, filtering, pulping a filter cake with 95% ethanol (100 mL) at room temperature for 1h, suction filtering, and vacuum drying the filter cake at 60 ℃ for 12h to obtain 44.30g of bright yellow solid with purity of 99.52% and yield of 97.2% (namely, the total yield of three steps of examples 2,4 and 6).
Example 7: synthesis of Compound VI
To a 500mL single-necked flask, compound V (20.00 g,49.84 mmol), potassium carbonate (20.67 g,149.52 mmol) and NMP (140 mL) were added at room temperature, and the mixture was stirred at 35℃for 4 hours to obtain a reaction solution of Compound VI, which was directly used in the next reaction.
Example 8: synthesis of Compound VII
To the whole reaction solution of compound VI (49.84 mmol) obtained in example 7 was added 3-hydroxyazetidine hydrochloride (5.46 g,49.84 mmol) with stirring, heating to 70 ℃ and stirring for 2 hours, filtering, adding acetic anhydride (11.20 g,109.71 mmol) to the filtrate, reacting at 25 ℃ for 1 hour, then slowly dropwise adding 10% citric acid (80.00 g), stirring for 0.5 hours, followed by filtering, washing the cake with water (15.00 g) twice, mixing the cake with 50% toluene+50% ethanol solution (80 mL), stirring for 2 hours at 70 ℃, cooling to room temperature and suction filtering, vacuum drying the cake at 60 ℃ for 8 hours to obtain 23.20g of off-white solid with purity of 99.41% yield 97.7% (i.e., total yield of both steps of examples 7 and 8).
Example 9: synthesis of Compound VIII
To a 250mL single-necked flask, a mixed solution of Compound VII (20.00 g,42.00 mmol) and ethyl acetate (60 mL), NCS (5.61 g,42.00 mmol), ethyl acetate (100 mL) and concentrated sulfuric acid (0.13 g,1.33 mmol) was added dropwise at 10℃and after the completion of the addition, the reaction was allowed to stand at 15℃for 4 hours. Thereafter, 3% sodium hydrogencarbonate solution (40.00 g) was added dropwise to quench, the solution was separated, and the organic phase was washed with 10% sodium sulfite (44.00 g) and concentrated to dryness at 40℃to give a concentrated organic matter.
The organics were concentrated by stirring with ethanol (100 mL) and 10% NaOH solution (80.00 g) was added. Then, the temperature was raised to 50℃and the reaction was carried out for 4 hours. After that, filtration was carried out, and 10% glacial acetic acid (108.00 g) was slowly added dropwise to the filtrate, and after the completion of the dropwise addition, the mixture was stirred at a constant temperature for 1 hour. After cooling to room temperature, the mixture was filtered, the filter cake was washed twice (40 mL), and dried under vacuum at 60℃for 16h to give 17.70g of a yellow solid, purity 99.22%, yield 95.6%.
1H NMR((400MHz,DMSO)δ14.63(brs,1H),8.38(d,J＝8.2Hz,1H),7.93(d,J＝13.8Hz,1H),7.81(dd,1H),6.75(s,2H),5.69(d,1H),4.61(dt,2H),4.45(m,1H),4.23(dt,2H)。
Example 10: synthesis of Compound I
To a 250mL single-necked flask, a mixed solution of Compound VIII (15.00 g,34.03 mmol) and isopropyl alcohol (90 mL), warmed to 50℃and meglumine (7.00 g,35.86 mmol) and water (30 mL) was added dropwise thereto, and the reaction was continued for 3 hours. After cooling to 10 ℃, filtering, and vacuum drying the filter cake for 16 hours at 50 ℃ to obtain 22.30g of white solid with the purity of 99.6 percent and the yield of 98.7 percent.
1H NMR(400MHz,DMSO)δ8.37(d,1H),7.90(t,J＝8.2Hz,1H),7.77(d,J＝13.8Hz,1H),6.67(s,2H),5.71(s,1H),4.65(s,1H),4.45(m,1H),4.12-3.71(m,4H),3.64-3.58(m,6H),3.47(s,3H),3.44-3.25(m,2H)。
The present invention is not limited to the above-mentioned embodiments, and any changes or substitutions that can be easily understood by those skilled in the art within the technical scope of the present invention are intended to be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.

Claims (10)

1. A process for the preparation of delafloxacin meglumine comprising:
step a: reacting reactant II with an acyl chloride reagent to form compound III;
step b: by reacting compound III with N, N-dimethylaminoacrylic acid C 1 -C 6 Alkyl ester reacts to generate a compound IV;
step c: reacting compound IV with 2, 6-diamino-3, 5-difluoropyridine to form compound V;
step d: the compound V is subjected to ring-closure reaction in the presence of alkali to obtain a compound VI;
step e: the acid addition salt of 3-hydroxy azetidine is subjected to substitution reaction with a compound VI, and the obtained substituted product is subjected to acylation reaction with an acylating agent, so that a compound VII is obtained;
step f: the compound VII and a chlorinating agent are subjected to chlorination reaction on a benzene ring, and the obtained product is subjected to hydrolysis reaction in the presence of alkali, so that the compound VIII is obtained; and
step g: reacting compound VIII with meglumine to form a salt to give delafloxacin meglumine of formula I:
Figure FDA0003455167700000011
wherein R may be C 1 -C 6 Alkyl or phenyl.
2. The method according to claim 1, wherein the acid chloride reagent in step a is thionyl chloride, oxalyl chloride, phosphorus trichloride or phosphorus pentachloride;
the mol ratio of the reactant II to the acyl chloride reagent is 1 (1-2);
the reaction of step a is carried out in an organic solvent selected from one or more of dichloromethane, toluene, acetonitrile and N, N-dimethylformamide;
the reaction temperature in step a is preferably from 0 to 200 ℃.
3. The process according to claim 1 or 2, wherein the acylating agent in step e is acetic anhydride, propionic anhydride, isopropyl anhydride, butyric anhydride, isobutyric anhydride, pivalic anhydride, hexanoic anhydride, benzoic anhydride, acetyl chloride or benzoyl chloride;
the molar ratio of the substituted product to the acylating agent is 1 (1-3);
the temperature of the acylation reaction is 20-50 ℃.
4. The process according to claim 1 or 2, wherein the chlorinating agent in step f is N-chlorosuccinimide;
the mol ratio of the compound VII to the chlorinating agent is 1 (1-1.5);
the chlorination reaction in the step f is carried out in an organic solvent, wherein the organic solvent is ethyl acetate, ethanol, acetonitrile, chloroform, tetrahydrofuran, carbon tetrachloride, dichloromethane, DMF or DME;
the chlorination reaction is carried out under the condition of strong acid;
the temperature of the chlorination reaction is 0-20 ℃.
5. The process according to claim 1 or 2, wherein in step b, N-dimethylaminoacrylic acid C 1 -C 6 The alkyl ester is N, N-dimethylamino methyl acrylate, N-dimethylamino ethyl acrylate, N-dimethylamino propyl acrylate, N-dimethylamino butyl acrylate, N-dimethylamino amyl acrylate or N, N-dimethylamino hexyl acrylate;
compound III and N, N-dimethylaminoacrylic acid C 1 -C 6 The molar ratio of the alkyl ester is 1 (1-1.5);
the reaction of step b is carried out in an organic solvent selected from one or more of dichloromethane, toluene, acetonitrile, triethylamine, N-dimethylformamide and N, N-dimethylacetamide;
the reaction temperature in step b is 0-200 ℃.
6. The process according to claim 1 or 2, wherein in step c, the molar ratio of compound IV to 2, 6-diamino-3, 5-difluoropyridine is 1 (1-1.5);
the reaction of step c is carried out in an organic solvent selected from one or more of acetonitrile, N-methylpyrrolidone, glacial acetic acid, anhydrous formic acid, tetrahydrofuran, ethyl acetate and ethanol;
the reaction temperature in step c is 0-80 ℃.
7. The process according to claim 1 or 2, wherein the base in step d is selected from K 2 CO 3 、Na 2 CO 3 NaOH and NaHCO 3 One or more of the following;
the reaction of step d is carried out in an organic solvent selected from one or more of N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, N-dimethylformamide and N, N-dimethylacetamide;
the reaction temperature in step d is 0-100 ℃.
8. The process according to claim 1 or 2, wherein the acid addition salt of 3-hydroxyazetidine in step e is 3-hydroxyazetidine hydrochloride, 3-hydroxyazetidine sulfate, 3-hydroxyazetidine nitrate, 3-hydroxyazetidine sulfonate, 3-hydroxyazetidine mesylate or 3-hydroxyazetidine succinate;
the molar ratio of compound VI to the acid addition salt of 3-hydroxyazetidine is 1 (1-1.5);
the substitution reaction in the step e is carried out in an organic solvent, wherein the organic solvent is selected from one or more of N-methyl pyrrolidone, dimethyl sulfoxide, acetonitrile, N-dimethylformamide and N, N-dimethylacetamide;
the temperature of the substitution reaction may be 20-100 ℃.
9. The process according to claim 1 or 2, wherein the base in step f is selected from K 2 CO 3 、Na 2 CO 3 NaOH and NaHCO 3 One or more of the following;
the temperature of the hydrolysis reaction is 30-60 ℃.
10. The process according to claim 1 or 2, wherein the molar ratio of compound VIII to meglumine is 1 (1-1.5), preferably 1 (1-1.2);
the reaction of step g is carried out in a solvent selected from one or more of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran and water;
the reaction temperature in step g is 30-70 ℃.
CN202210004950.6A 2022-01-04 2022-01-04 Preparation method of delafloxacin meglumine Pending CN116425720A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210004950.6A CN116425720A (en) 2022-01-04 2022-01-04 Preparation method of delafloxacin meglumine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210004950.6A CN116425720A (en) 2022-01-04 2022-01-04 Preparation method of delafloxacin meglumine

Publications (1)

Publication Number Publication Date
CN116425720A true CN116425720A (en) 2023-07-14

Family

ID=87091326

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210004950.6A Pending CN116425720A (en) 2022-01-04 2022-01-04 Preparation method of delafloxacin meglumine

Country Status (1)

Country Link
CN (1) CN116425720A (en)

Similar Documents

Publication Publication Date Title
JP2002338516A (en) Method of production for 2-halogenated benzoic acids
CN111675662A (en) Preparation method of 2-trifluoromethyl substituted quinazolinone compound
CN112174989A (en) Preparation method of clitorium
JP2022508494A (en) Method for Producing Morpholine Quinazoline Compound and its Intermediate
KR20010024031A (en) Method for The Synthesis of Quinoline Derivatives
CN116425720A (en) Preparation method of delafloxacin meglumine
CN105732660B (en) The preparation method of lavo-ofloxacin intermediate
JPS63316757A (en) 3-amino-2-substituted benzoylacrylic acid derivative
CN102105433A (en) 6-nitro acetophenone compounds, preparation methods and uses thereof
US5659051A (en) Process of producing 2-cyano-4-oxo-4H-benzopyran compounds
WO2020082605A1 (en) Pyrazolyl azophenol compound and synthesis and derivation thereof
CN109988075A (en) A kind of preparation method of bromfenac sodium
CN110003101B (en) Apatinib intermediate and preparation method thereof
CN101723954B (en) Technique for preparing olanzapine
CN110563721A (en) Preparation method of azasetron hydrochloride
CN110981781A (en) Synthetic method of indometacin and analogue thereof
CN110606839A (en) Green synthesis method of polysubstituted quinazoline derivative
CN109651179B (en) 2- (2-aminobenzoyl) benzoic acid derivatives and process for preparing the same
CN104418805B (en) Dabigatran etexilate intermediate as well as preparation method and application thereof
CN108658981A (en) A kind of synthetic method of the bromo- 4- methoxyl groups hydrogen of 6--pyrazoles [1,5-a] pyridine -3- formonitrile HCNs
CN114349684B (en) Synthetic method of benzo [ c, d ] indole imine derivative
JP2000119221A (en) Production of (2,4,5-trifluoro-3-methoxybenzoyl) acetic acid ester derivative and its production intermediate
CN107778227B (en) 4-fluoro-6-trifluoromethyl-3-picolinate intermediate and synthetic method and application thereof
CN113582926B (en) Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof
CN114621109B (en) Synthesis method of apatamide and intermediate thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd.